NEWTOWN, Pa.--(BUSINESS WIRE)--March 21, 2006--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today reported that the European Patent Office has published on its web site that patent application 02731267.7 will be allowed. This patent has a priority date of April 5, 2002 and covers the use of sub anti-microbial doxycycline in the treatment of acne and rosacea, including Oracea(TM).
